Search – Page 95 – Indianapolis Business Journal

Home » Search

Articles

Eskenazi launches $50M effort to take brain care around the world

October 9, 2015

The safety-net hospital system in Indianapolis will create the Center for Brain Care Innovation and try to use telemedicine and a digital avatar to reach as many as 150,000 Hoosiers and 10 million patients outside Indiana by 2030.

Lilly to add 50 employees at R&D center in New York

October 9, 2015

The drugmaker is trying to beef up its work on using the immune system to fight cancer. Indianapolis will remain Lilly’s main hub for research and development.

Go figure: As patients’ anger over costs spikes, health care prices barely budge

October 9, 2015

Patients’ anger over high deductibles and high drug prices is spurring presidential candidates to respond—even as the actual prices of health care services are growing slower than at any time since 1990.

Novel approach to Alzheimer’s care set for Midwestern rollout

October 8, 2015

Dr. Malaz Boustani leads a 26-person team at Eskenazi Health that is showing the group's approach to health care can improve the mental health of both dementia patients and their care givers.

Puerto Rico plans new corporate tax to replace excise levy

September 30, 2015

Puerto Rico officials are looking to replace an expiring tax with a new levy to draw much-needed revenue from the world’s best-selling medications while seeking to avoid driving U.S. manufacturers such as Eli Lilly and Co. from the commonwealth.

Lilly stock climbs on positive arthritis drug test

September 29, 2015

A potential rheumatoid arthritis treatment from drugmakers Eli Lilly and Co. and Incyte Corp. fared better than another drug in late-stage testing, Lilly said Tuesday.

Settlement clears way for Lilly to launch once-a-day insulin

September 28, 2015

The settlement with France-based Sanofi SA clears up uncertainty over a drug that could rack up more than $1 billion in sales by 2020, according to Wall Street analysts.

The Interview Issue: John Lechleiter

September 24, 2015

John Lechleiter, CEO of Eli Lilly and Co., said the company remained confident about its drug pipeline even after it weathered a string of failed clinical trials.

Rolls-Royce to run new R&D facility at Purdue tech park

September 23, 2015

The global firm with extensive Indiana operations plans to occupy a 40,000-square-foot building to be constructed in the Purdue Research Park Aerospace District, a 980-acre technology park in West Lafayette.

Purdue’s Chao Center regains drug, slashes $360-per-pill price

September 22, 2015

An Indiana not-for-profit has dropped the price of a drug for multi-drug resistant tuberculosis roughly 90 percent after re-acquiring rights to the medicine from Rodelis Therapeutics.

Robbins takes on additional title at Lilly Endowment

September 22, 2015

N. Clay Robbins, the president and CEO of the Lilly Endowment, has been given the additional title of chairman at the Indianapolis-based private charitable foundation.

Analyst: Lilly’s Jardiance diabetes pill could be a $6 billion-a-year blockbuster

September 21, 2015

It looks like Eli Lilly and Co. finally has a drug that can replace its former stars Zyprexa and Cymbalta. The most bullish analysts think Jardiance can surpass those $5 billion-a-year blockbusters.

Lilly stock performs big despite analyst projections

September 19, 2015

Analysts have consistently given the Indianapolis-based company some of the lowest ratings among a group of 16 large drugmakers, but Lilly shares have been on a five-year rally.

Transcript: IBJ Commercial Real Estate and Construction Power Breakfast

September 18, 2015

Indianapolis Business Journal gathered leaders in the state’s commercial real estate and construction industry for a Power Breakfast panel discussion Sept. 10.

Lilly’s heart study sets up showdown with Novo’s Victoza

September 18, 2015

Unprecedented results from a cardiovascular study on a diabetes medicine sold by Eli Lilly and Co. turns up the pressure on rival Novo Nordisk, which will release data from a similar study on its competing drug next year.

PETERSON: 16 Tech is rare opportunity for Indianapolis

September 18, 2015

16 Tech would bring together many of Indianapolis’ existing strengths—our research universities, life sciences expertise and vibrant technology sector—to spark new companies and jobs.

Jardiance study lifts Lilly shares to 15-year high

September 18, 2015

Eli Lilly shares soared Thursday after study results showed Jardiance sharply reduced chances of dying in diabetic patients at high risk of heart complications. The study prompted at least one analyst to predict the drug could bring in billions of dollars by the end of the decade.

« Previous 1 … 93 94 95 96 97 … 221 Next »

Search Results

4,411 results for '\"eli lilly\"'

Articles

Eskenazi launches $50M effort to take brain care around the world

Lilly to add 50 employees at R&D center in New York

Go figure: As patients’ anger over costs spikes, health care prices barely budge

Novel approach to Alzheimer’s care set for Midwestern rollout

Puerto Rico plans new corporate tax to replace excise levy

Lilly stock climbs on positive arthritis drug test

Settlement clears way for Lilly to launch once-a-day insulin

The Interview Issue: John Lechleiter

Rolls-Royce to run new R&D facility at Purdue tech park

Purdue’s Chao Center regains drug, slashes $360-per-pill price

Robbins takes on additional title at Lilly Endowment

Analyst: Lilly’s Jardiance diabetes pill could be a $6 billion-a-year blockbuster

Transcript: IBJ Commercial Real Estate and Construction Power Breakfast

Lilly’s heart study sets up showdown with Novo’s Victoza

PETERSON: 16 Tech is rare opportunity for Indianapolis

Jardiance study lifts Lilly shares to 15-year high

Simon proposing major Circle Centre revamp

Lilly shares jump on latest data from diabetes drug

Lilly leaps into new frontier of cancer drugs